Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANII: Encorafenib and Binimetinib in BRAF V600E Mutated NSCLC
NCT05195632Phase 2Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of encorafenib, binimetinib in non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Started Jun 2022; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05195632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195632.